M&A Deal Summary |
|
---|---|
Date | 2021-03-09 |
Target | Novitium Pharma |
Sector | Life Science |
Buyer(s) | ANI Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 164M USD |
Advisor(s) | Leerink Partners LLC (Financial) Orrick, Herrington & Sutcliffe LLP (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2001 |
Sector | Life Science |
Employees | 369 |
Revenue | 208M USD (2020) |
ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI has several ANDAs pending FDA approval and in various stages of development. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.
DEAL STATS | # |
---|---|
Overall | 14 of 14 |
Sector (Life Science) | 12 of 12 |
Type (Add-on Acquisition) | 2 of 2 |
State (New Jersey) | 3 of 3 |
Country (United States) | 11 of 11 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-01-09 |
Amerigen Pharmaceuticals - Commercial and Pipeline Generic Products
Suzhou, China Amerigen Pharmaceuticals' Commercial and Pipeline Generic Products includes a U.S. portfolio of 23 generic products. |
Buy | $53M |